Shattuck Labs posts corporate presentation outlining DR3 antibody program for inflammatory diseases

Shattuck Labs, Inc.

Shattuck Labs, Inc.

STTK

0.00
  • Shattuck Labs outlined its focus on DR3-blocking antibodies for inflammatory and immune-mediated diseases, led by SL-325 targeting the TL1A receptor.
  • RECEPTIVE-CD1 Phase 2b trial of SL-325 in Crohn’s disease slated to start in Q3 2026; 12-week induction data targeted for 1H 2028.
  • Cash, cash equivalents, short-term investments of $208.3 million as of June 30, 2026; runway expected into 2029.
  • Phase 1 program for SL-325 completed in 72 healthy participants; estimated half-life 16 days; anti-drug antibody rate 3.7%.
  • Preclinical pipeline includes SL-846 DR3 x IL-23R bispecific with Phase 1 start planned for 1H 2027, alongside half-life-extended DR3 antibody SL-425.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shattuck Labs Inc. published the original content used to generate this news brief on July 14, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.